<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114230</url>
  </required_header>
  <id_info>
    <org_study_id>2009002</org_study_id>
    <nct_id>NCT01114230</nct_id>
  </id_info>
  <brief_title>A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer</brief_title>
  <official_title>A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agensys, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK)
      of AGS-16M8F administered in subjects with advanced renal cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by recording adverse events, vital signs and laboratory assessments</measure>
    <time_frame>For 12 weeks during treatment period and up to 4 weeks follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic variables assessment through analysis of blood samples</measure>
    <time_frame>Up to day 15 for cycle 1 and cycle 4 and pre-dose for cycles 2 and 3; every 3 weeks during the second 12 weeks of treatment; and if subject continues on study drug, every 12 weeks thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-AGS-16M8F antibody formation</measure>
    <time_frame>Baseline; up to day 64 during the first 12 weeks; and if subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Tumor Response (complete or partial response)</measure>
    <time_frame>Baseline and every 12 weeks while on study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Pharmacokinetics of AGS-16M8F</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGS-16M8F</intervention_name>
    <description>IV</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_label>Dose Level 6</arm_group_label>
    <arm_group_label>Dose Level 7</arm_group_label>
    <arm_group_label>Dose Level 8</arm_group_label>
    <arm_group_label>Dose Level 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis (recent or remote) of metastatic renal cell
             carcinoma (including papillary, clear cell, and excluding transitional cell types)
             that is not amenable to cure by surgery or other means.

          -  Non-measurable or measurable disease according to Response Criteria for Solid Tumors
             (RECIST Version 1.1)

          -  Eastern Cooperative Group (ECOG) performance status of 0-1

          -  Negative pregnancy test (women of childbearing potential)

          -  Hematologic function, as follows:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               -  Platelet count ≥ 100 x 109/L

               -  Hemoglobin ≥ 9 g/dL (transfusions are allowed)

          -  Renal function, as follows:

               -  creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular
                  filtration rate (GFR) &gt; 50 mL/min if creatinine &gt; 1.5x ULN

          -  Hepatic function, as follows:

               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN
                  or ≤ 5x ULN if known liver metastases

               -  Total bilirubin ≤ 1.5 x ULN

          -  International Normalized Ratio (INR) &lt; 1.3 (or ≤ 3.0 if on therapeutic
             anticoagulation)

          -  Women and men of childbearing potential must be advised and agree to practice
             effective methods of contraception during the course of the study and for four weeks
             after the last AGS-16M8F infusion administration

        Exclusion Criteria:

          -  Past or present documented central nervous system (CNS) tumor or CNS metastasis

          -  Use of any investigational drug (including marketed drugs not approved for this
             indication) within 4 weeks prior to screening

          -  History of thromboembolic events and bleeding disorders ≤ 3 months (e.g., DVT or PE)

          -  Active angina or Class III or IV Congestive Heart Failure (New York Heart Association
             CHF Functional Classification System) or clinically significant cardiac disease within
             12 months of study enrollment, including myocardial infarction, unstable angina, grade
             2 or greater peripheral vascular disease, congestive heart failure, uncontrolled
             hypertension, or arrythmias not controlled by outpatient medication

          -  Major surgery (that requires general anesthesia) within 4 weeks of study enrollment

          -  Women who are pregnant (confirmed by positive pregnancy test) or lactating

          -  Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis
             B surface antigen

          -  Active infection requiring treatment with systemic (intravenous or oral)
             anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Agensys, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Renal Cell Carcinoma</keyword>
  <keyword>Advanced Kidney Cancer</keyword>
  <keyword>AGS-16M8F</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

